A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome
Phase: PHASE2
Conditions: Autosomal-dominant Hyper-IgE Syndrome
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of 
One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE 
Syndrome 
NIAID Protocol Number: 
17-I-0017 
Version Number: 
3.0 
Date: 
August 13, 2018 
Investigational New  
Drug (IND) Number: 
17230 
IND Sponsor: 
Office of Clinical Research Policy and Regulatory Operations 
(OCRPRO) 
Division of Clinical Research (DCR) 
National Institute of Allergy and Infectious Diseases (NIAID) 
National Institutes of Health (NIH) 
Sponsor Medical Monitor: H. Preston Holley, MD, FIDSA 
 
Medical Monitor 
 
Leidos Biomedical Research 
 
5705 Industry Lane 
Frederick, MD 21701 
Phone: 301 228-4005 
Email: Preston.Holley@fnlcr.nih.gov  
Pharmaceutical Support 
Provided by:  
 
NovaDigm Therapeutics, Inc. 
4201 James Ray Drive 
Technology Transfer Building 
Grand Forks, ND 58202 
OHRP Assurance: FWA00011288 
Principal Investigator: 
Alexandra Freeman, MD 
Laboratory of Clinical Immunology and Microbiology (LCIM) 
Building 10 Room 11N234 
10 Center Drive 
Bethesda, MD 20814 
Phone: 301-594-9045 
Email: freemaal@mail.nih.gov  
Conducted by: 
 
LCIM, NIAID, NIH 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 2 of 47 
Study Staff Roster
Associate Investigators: 
Lisa Barnhart, RN, MSN 
LCIM/NIAID 
Phone: (301) 496-5270 
Email: lbarnhart@niaid.nih.gov  
 
Angelique Biancotto, PhD 
Center for Human Immunology 
Autoimmunity, and Inflammation 
(CHI)/National Heart, Lung and Blood 
Institute (NHLBI) 
Phone: (301) 594-0060 
Email: biancoa@mail.nih.gov  
 
Jinguo Chen, MD 
CHI/NHLBI 
Phone: (301) 594-4636 
Email: chenjinguo@mail.nih.gov  
 
Elise Ferré, PA-C, MPH 
LCIM/NIAID 
Phone: (301) 496-8985 
Email: elise.ferre@nih.gov  
 
Steven Holland, MD 
LCIM/NIAID 
Phone: (301) 402-7684 
Email: SHOLLAND@niaid.nih.gov  
 
Sally Hunsberger, PhD 
Biostatistics Research Branch/NIAID 
Phone: (240) 669-5257 
Email: sallyh@niaid.nih.gov  
 
Michail Lionakis, MD 
LCIM/NIAID 
Phone: (301) 443-5089 
Email: lionakism@niaid.nih.gov  
 
 
Amanda Urban, CRNP  
Leidos Biomedical Research, Inc 
LCIM/NIAID 
Phone: (301) 451-3191 
Email: urbana@niaid.nih.gov  
 
Pamela Welch, RN, BSN 
Leidos Biomedical Research, Inc 
LCIM/NIAID 
Phone: (301) 402-0449 
Email: welchp@mail.nih.gov  
 
 
External Collaborators: 
John P. Hennessey, Jr, PhD 
NovaDigm Therapeutics, Inc. 
4201 James Ray Drive 
Technology Transfer Building 
Grand Forks, ND 58202 
Phone: (267) 640-5189 
Email: john_hennessey@novadigm.net 
Dr. Hennessey will supply the vaccine from 
NovaDigm. He will also perform the 
serologic assays, including anti-rAls3 IgG 
and IgA1 responses, at baseline and to the 
vaccine on the de-identified samples. He 
will also assist in the data analysis of the 
cytokine responses to the vaccination.  
 
 
 
 
External Collaborators (Cont.): 
Jack E. Edwards, Jr, MD 
Los Angeles Biomedical Research Institute  
Harbor-UCLA Medical Center 
Division of Infectious Diseases (RB2) 
1124 W. Carson Street 
Torrance, CA 90502 
Phone: (310) 222-3813 
Email: jedwards@labiomed.org 
Dr. Edwards will assist in the interpretation 
of the serologic and cytokine responses to 
the vaccines on de-identified samples. 
 
 
 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 3 of 47 
Study Site: 
NIH Clinical Center (CC) 
10 Center Drive 
Bethesda, MD 20814 
 
Institutional Review Board (IRB): 
NIAID IRB 
5601 Fishers Lane 
Bethesda, MD 20892
 
 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 4 of 47 
Table of Contents 
Study Staff Roster ............................................................................................................................ 2 
Table of Contents ............................................................................................................................ 4 
List of Abbreviations ....................................................................................................................... 7 
Protocol Summary ........................................................................................................................... 8 
Précis ............................................................................................................................................. 10 
1 
Background Information and Scientific Rationale ................................................................ 11 
 
Background Information ............................................................................................... 11 
 
Description of the Study Agent ............................................................................. 11 
 
Summary of Preclinical Studies of NDV-3 and NDV-3A .................................... 11 
 
Summary of Relevant Clinical Studies of NDV-3 and NDV-3A .......................... 13 
 
Summary of Relevant Clinical Studies of Other Vaccines ................................... 14 
 
Rationale ........................................................................................................................ 15 
2 
Study Objectives .................................................................................................................... 16 
 
Primary Objective .......................................................................................................... 16 
 
Secondary Objectives .................................................................................................... 16 
 
Exploratory Objectives .................................................................................................. 16 
3 
Study Design .......................................................................................................................... 17 
 
Description of the Study Design .................................................................................... 17 
 
Study Endpoints ............................................................................................................ 17 
 
Primary Endpoint ................................................................................................... 17 
 
Secondary Endpoints ............................................................................................. 17 
 
Exploratory Endpoints ........................................................................................... 17 
4 
Study Population .................................................................................................................... 18 
 
Recruitment Plan ........................................................................................................... 18 
 
Subject Inclusion Criteria .............................................................................................. 19 
 
Subject Exclusion Criteria ............................................................................................. 19 
 
Justification for Exclusion of Special Populations ........................................................ 21 
 
Exclusion of women .............................................................................................. 21 
 
Exclusion of minors ............................................................................................... 21 
5 
Study Agent/Interventions ..................................................................................................... 21 
 
Disposition and Dispensation ........................................................................................ 21 
 
Formulation, Packaging, and Labeling .................................................................. 21 
 
Study Agent Storage and Stability ................................................................................ 22 
 
Preparation, Administration, and Dosage of Study Agent ............................................ 22 
 
Study Product Accountability Procedures ..................................................................... 22 
 
Assessment of Subject Compliance with Study Agent ................................................. 22 
 
Concomitant Medications and Procedures .................................................................... 22 
 
Prohibited Medications and Procedures ........................................................................ 23 
6 
Study Schedule and Procedures ............................................................................................. 23 
 
Screening (Day −28 to baseline) ................................................................................... 23 
 
Baseline Visits (Days –3 to 0) ....................................................................................... 24 
 
Visit for Vaccination (Days 0 to 2) ............................................................................... 24 
 
Follow-up Visits ............................................................................................................ 25 
 
Early Termination Visit ................................................................................................. 26 
 
Pregnancy and Follow-up Visit ..................................................................................... 26 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 5 of 47 
7 
Potential Risks and Benefits .................................................................................................. 26 
 
Potential Risks ............................................................................................................... 26 
 
Potential Benefits ........................................................................................................... 28 
8 
Research Use of Stored Human Samples, Specimens, or Data ............................................. 28 
9 
Data Sharing Plan .................................................................................................................. 29 
10 Remuneration Plan for Participants ....................................................................................... 29 
11 Assessment of Safety ............................................................................................................. 30 
 
Definitions ..................................................................................................................... 30 
 
Documenting, Recording, and Reporting Adverse Events ............................................ 31 
 
Investigator Assessment of Adverse Events .................................................................. 32 
 
Severity .................................................................................................................. 32 
 
Causality ................................................................................................................ 33 
 
Investigator Reporting Responsibilities to the Sponsor ................................................ 34 
 
Adverse Events ...................................................................................................... 34 
 
Reactogenicity ....................................................................................................... 34 
 
Serious Adverse Events ......................................................................................... 34 
 
Unanticipated Problems ......................................................................................... 35 
 
Pregnancy .............................................................................................................. 35 
 
Investigator Reporting Procedures to the NIAID IRB .................................................. 36 
 
Definitions ............................................................................................................. 36 
 
Expedited Reporting to the NIAID IRB ................................................................ 36 
 
Waiver of Reporting Anticipated Protocol Deviations, Expected UPnonAEs, and 
Deaths to the NIAID IRB ...................................................................................................... 36 
 
Annual Reporting to the NIAID IRB .................................................................... 37 
 
Sponsor’s Reporting Responsibilities............................................................................ 37 
 
Halting Rules for the Protocol ....................................................................................... 37 
 
Reporting a Study Halt .......................................................................................... 38 
 
Resumption of a Halted Study ............................................................................... 38 
 
Withdrawal Criteria for an Individual Participant ......................................................... 38 
 
Replacement of Withdrawn Participant ................................................................. 38 
 
Safety Oversight ............................................................................................................ 39 
 
Safety Review and Communications Plan ............................................................ 39 
 
Sponsor Medical Monitor ...................................................................................... 39 
 
Safety Monitoring Committee ............................................................................... 39 
12 Site Monitoring Plan .............................................................................................................. 39 
13 Statistical Considerations ...................................................................................................... 40 
 
Study Hypotheses .......................................................................................................... 40 
 
Sample Size Justification ............................................................................................... 40 
 
Description of the Analyses ........................................................................................... 40 
 
Secondary Endpoints ..................................................................................................... 40 
14 Ethics/Protection of Human Subjects .................................................................................... 41 
 
Informed Consent Process ............................................................................................. 41 
 
Non-English-Speaking Participants ...................................................................... 41 
 
Participant Confidentiality ............................................................................................. 42 
15 Data Handling and Record Keeping ...................................................................................... 42 
 
Data Capture and Management ..................................................................................... 42 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 6 of 47 
 
Record Retention ........................................................................................................... 42 
16 Scientific References ............................................................................................................. 44 
Appendix A: Schedule of Procedures/Evaluations ........................................................................ 45 
Appendix B: Blood Draw Volumes .............................................................................................. 47 
 
 
 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 7 of 47 
List of Abbreviations 
AD-HIES 
autosomal-dominant hyper IgE syndrome 
AE 
adverse event 
Als3 
agglutinin-like sequence 3 
AlOH 
Aluminum hydroxide 
ALP 
alkaline phosphatase 
ALT 
alanine transaminase 
AR 
adverse reaction 
AST 
aspartate transaminase 
CC 
Clinical Center 
CFR 
Code of Federal Regulations 
CHI 
Center for Human Immunology, Autoimmunity and Inflammation 
CRIS 
Clinical Research Information System 
CRIMSON 
Clinical Research Information Management System of the NIAID 
CSO 
Clinical Safety Office 
DCR 
Division of Clinical Research 
ED50 
median effective dose 
ELISA 
enzyme-linked immunosorbent assay 
ELISpot 
enzyme-linked immunospot 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
HRPP 
Human Research Protections Program 
ICH 
International Council on Harmonisation 
ID 
intradermal(ly) 
IgE 
Immunoglobulin E 
IgG 
Immunoglobulin G 
IND 
Investigational New Drug 
IM 
intramuscular(ly) 
IRB 
Institutional Review Board 
LCID 
Laboratory of Clinical Infectious Disease 
NHLBI 
National Heart, Lung and Blood Institute 
NIAID 
National Institute of Allergy and Infectious Diseases 
NIH 
National Institutes of Health 
OCRPRO 
Office of Clinical Research Policy and Regulatory Operations 
OHRP 
Office of Human Research Protections 
PBMC 
peripheral blood mononuclear cell 
PCR 
polymerase chain reaction 
PI 
principal investigator 
r 
recombinant 
SAE 
serious adverse event 
SAR 
suspected adverse reaction 
SCORAD 
SCORing Atopic Dermatitis 
SERF 
Safety Expedited Report Form 
SMC 
Safety Monitoring Committee 
SRCP 
Safety Review and Communications Plan 
SUSAR 
serious and unexpected suspected adverse reaction 
ULN 
upper limit of normal 
UP 
unanticipated problem 
UPnonAE 
unanticipated problem that is not an adverse event 
VVC 
vulvovaginal candidiasis 
 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 8 of 47 
Protocol Summary 
Short Title: 
NDV-3A Vaccine Study 
Clinical Phase: 
2a 
Sample Size: 
N = 40; 20 with autosomal-dominant hyper-IgE syndrome 
(AD-HIES) and 20 healthy volunteers 
Accrual Ceiling: 
N = 50 
Study Population: 
Adults (18-55 years), either healthy volunteers or diagnosed with 
AD-HIES 
Accrual Period: 
12 months (Subsequent data analysis until approximately 
December 2019.) 
Study Duration: 
Start Date: May 2017 
End Date: December 2019 
Total length of individual subject participation: approximately 
6-7 months 
Study Design: 
This is a single-dose, open-label study to evaluate the safety, 
tolerability, and immunogenicity of the NDV-3A vaccine in 
healthy adult volunteers and adult volunteers with AD-HIES 
Study Agent/ 
Intervention Description: 
NDV-3A, a vaccine containing recombinant Candida albicans 
agglutinin-like sequence 3 (rAls3) protein as the antigen, 
formulated with aluminum hydroxide (AlOH) adjuvant in 
phosphate-buffered saline. Participants will receive a single 
0.5-mL dose containing 300 µg of rAls3 and 0.5 mg of aluminum 
as AlOH, delivered via intramuscular injection. 
Primary Objective: 
To assess anti-rAls3 antibody titers in response to the study 
vaccine 14 days after vaccination. 
Secondary Objectives: 
1. To evaluate the safety of the study vaccine in adults with 
AD-HIES. 
2. To assess anti-rAls3 antibody titers in response to the study 
vaccine 6 months after vaccination. 
Primary Endpoint: 
Percent of each group with at least a four-fold increase in 
anti-rAls3 antibody titer 2 weeks after vaccination.  

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 9 of 47 
Secondary Endpoints: 
1. Frequency of injection site and systemic AEs in AD-HIES 
affected patients and healthy volunteers. 
 
2. Anti-Als3 antibody titers at 6 months after vaccination in 
patients with AD-HIES and healthy volunteers. 
 
 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 10 of 47 
Précis 
Autosomal-dominant hyper-IgE syndrome (AD-HIES) is characterized by recurrent 
Staphylococcus aureus and Candida epithelial infections, which is thought to be due, in part, to a 
lack of Th17 cell differentiation, thus impairing epithelial immunity. Treatment of AD-HIES is 
primarily supportive with prophylactic antibiotics; however, this is limited by microbial 
resistance and intolerance of medications, and infections do still occur. Immunological 
intervention with a vaccine could improve quality of life by preventing these infections 
altogether. 
The NDV-3A vaccine consists of a recombinant protein derived from the Candida Als3 adhesion 
protein. This protein is homologous to surface proteins on S aureus and has been shown in 
preclinical studies to protect against both intravascular and subcutaneous challenge with 
S aureus. Therefore, NDV-3A represents not only the first antifungal vaccine, but also the first 
vaccine to provide cross-kingdom protection. In Phase 1 and Phase 2 studies in healthy 
volunteers (150 receiving vaccine), the safety profile of this vaccine is very reassuring as the 
vaccine elicits a strong antibody response after a single dose in all vaccinees as well as a Th1 
and/or Th17 response in the majority of vaccinees. We will enroll 20 healthy adult volunteers 
and 20 adults with AD-HIES in an open-label, single-dose study to assess the immunological 
response to and the safety/tolerability of the NDV-3A vaccine. We anticipate an increase in 
baseline anti-Als3 IgG within 2 weeks post-vaccination. 
 
 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 11 of 47 
1 Background Information and Scientific Rationale 
 
Background Information 
 
Description of the Study Agent 
The NDV-3 and NDV-3A vaccines (NovaDigm Therapeutics [Grand Forks, ND, USA]) were 
initially developed for the prevention of Candida sp infections. The vaccines contain a purified 
recombinant protein derived from the 416-residue N-terminal region of the C albicans 
agglutinin-like sequence 3 protein (Als3). Als3 is an adhesin and an invasin that helps C albicans 
adhere to and invade host cells.1 The recombinant (r) Als3 antigen increases survival in mice 
given a systemic challenge with C albicans,2 reduces kidney fungal burden in mice given a 
systemic challenge with any of the five most common species of Candida (Ibrahim, unpublished 
data), and reduces vaginal fungal burden in mice given an intravaginal challenge with 
C albicans.3 Surprisingly, rAls3 shows substantial homology to 2 surface proteins on 
Staphylococcus aureus.4 In preclinical mouse studies, the vaccine has been highly protective 
against tail vein or subcutaneous challenge with S aureus , including infections caused by 
methicillin-resistant strains.5 This is one of the first examples of cross-kingdom protection 
conveyed by a vaccine, likely exemplifying convergent evolution of a mechanism of adherence 
and invasion to human cells by two different human pathogens.6 
The NDV-3 vaccine contains the rAls3 protein with an N-terminal 15-amino acid addition. This 
addition contains a six-histidine tag to facilitate purification. The NDV-3A vaccine contains the 
rAls3 protein without the extra amino acid residues. Both recombinant proteins are expressed in 
a Saccharomyces cerevisiae system. Other licensed vaccines, such as Gardasil for human 
papillomavirus and Recombivax HB for hepatitis B (Merck & Co, Inc [Kenilworth, NJ, USA]), 
are also derived from yeast expression systems.7 
The NDV-3 and NDV-3A vaccines are formulated in an AlOH suspension that serves as an 
adjuvant.7 
 
Summary of Preclinical Studies of NDV-3 and NDV-3A 
Pharmacology studies in mice demonstrated a protective effect of rAls3 against infection by 
Candida sp and S aureus. In one study, mice that were inoculated with rAls3 + adjuvant and then 
challenged with S aureus demonstrated an increased survival rate relative to mice inoculated 
with adjuvant alone.7 In a second study, mice were inoculated with 2 doses of rAls3 + adjuvant 
or adjuvant alone, and then CD3+ T cells and B220+ B cells were collected. Female Balb/c mice 
then received either the harvested T or B cells, and then were challenged with C albicans or 
S aureus. Mice that received T cells from mice vaccinated with rAls3 + adjuvant demonstrated 
significantly (p < 0.01) enhanced survival for both challenges relative to mice who received 
B cells from vaccinated mice and either T or B cells from unvaccinated mice.7 In a third study, 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 12 of 47 
female mice vaccinated with two doses of NDV-3A and then challenged with C albicans showed 
substantial reductions in vaginal fungal burden relative to control mice that only received the 
adjuvant.7 
Rhesus macaques inoculated with rAls3 + adjuvant displayed a dramatic increase in anti-rAls3 
antibody titers post-vaccination relative to monkeys inoculated with adjuvant alone.7  
Two other studies were conducted to compare the activity of the NDV-3 and NDV-3A vaccines 
in mice. In the first, mice were vaccinated on study days 0 and 21 with up to 100 µg of antigen. 
An immunogenicity assay to measure the geometric mean of serum IgG titer of each dose group 
showed that IgG response for both antigens plateaued at doses of approximately 5 µg. 
In the second study, mice received 2 doses of NDV-3 or NDV-3A, separated by 3 weeks, at 
doses ranging from 0.02 to 5 µg of antigen. The median effective dose (ED50) for NDV-3 was 
approximately 0.57 µg, while the ED50 for NDV-3A was approximately 0.10 µg. The lower ED50 
for NDV-3A means that less antigen was required for mice who received that vaccine to 
seroconvert than was required for mice vaccinated with NDV-3. The results of these studies as 
well as the intravaginal challenge study described above demonstrate that NDV-3 and NDV-3A 
have similar biological activity in mouse models. 
A Good Laboratory Practice–compliant toxicology study was conducted in New Zealand white 
rabbits. Rabbits received either a 300-µg dose of the NDV-3 vaccine or placebo at Days 1, 15, 
and 29 via intramuscular (IM) injection. No test article–related effects were noted for in-life 
examination (survival, clinical observations, body weight and temperature, skin irritation, and 
ophthalmoscopic evaluations) and clinical pathology (hematology, clinical chemistry, C-reactive 
protein, serum protein electrophoresis, and urinalysis). 
There was an observable decrease in the weights of adrenal glands between males who received 
the vaccine and the other groups. However, because this difference was sex-specific and there 
was no microscopic correlation, this effect was not likely to be the result of the vaccine.  
Red discoloration of the skeletal muscle was observed at two of the injection sites of rabbits that 
received the vaccine. This correlated with microscopic findings of skeletal muscle myofiber 
degeneration/necrosis, hemorrhage, and presence of inflammatory heterophils, mononuclear 
cells, and foamy macrophages. These changes resolved at recovery, except for the continued 
increase in incidence and/or severity of foamy macrophages. All of these changes indicated a 
typical injection site inflammatory reaction. 
The FDA did not require a separate toxicology study of NDV-3A as they considered NDV-3 and 
NDV-3A to be biologically equivalent based on the in vitro and in vivo preclinical data provided.   

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 13 of 47 
 
Summary of Relevant Clinical Studies of NDV-3 and NDV-3A 
Two phase 1 clinical studies of NDV-3 have been completed to date. Additionally, a phase 1b/2a 
study has completed enrollment.  
In the first phase 1 study, 40 healthy adults, ages 19 to 47 years, were randomized into one of 
three dose groups: placebo (n = 10), 30-µg rAls3 (n = 15), or 300-µg rAls3 (n = 15). Injections 
were administered IM. Several research participants who had received the vaccine received a 
booster after 6 months at the same dose as the initial injection. The most common complaint 
among all groups at both the first and second doses was injection site reactions. All reactions 
resolved over time with no further complications, and no serious adverse events (SAEs) were 
observed. 
All participants who received the vaccine had at least a four-fold increase in plasma anti-Als3 
IgG titers against rAls3 at Day 14 compared to placebo-dosed participants. Plasma anti-Als3 IgA 
titer was similarly increased in vaccinees compared to placebo recipients. Participants who 
received the 300-µg dose displayed a greater increase than those who received the 30-µg dose. 
These responses suggest that natural exposure to Candida has primed these individuals and that 
the vaccine induces an anamnestic immune response. A booster dose at 6 months after the first 
dose elicited a modest increase in the anti-Als3 IgG and IgA titers.  
Additionally, ELISpot assays of harvested PBMCs demonstrated that within a few weeks of 
vaccination the majority of participants who received either dose of the vaccine had an increased 
number of PBMCs showing Als3-specific production of IFN-γ and/or IL-17A relative to 
placebo-dosed participants. The response rate was faster in participants dosed at 300 µg than at 
30 µg. A booster dose at 6 months after the first dose elicited what appears to be a substantial 
increase in the percent of vaccinees with an increased number of PBMCs showing Als3-specific 
production of IFN-γ and/or IL-17A relative to placebo-dosed participants, but there was no 
significant difference between the two doses. 
In the second phase 1 study, 160 healthy adult volunteers were randomized to one of four dose 
groups (n = ~40 per group) each receiving a single dose of vaccine: placebo, 30 µg rAls3 without 
alum adjuvant administered via intradermal (ID) injection, or 300 µg rAls3 (with or without 
alum adjuvant) administered via IM injection. Injection site reactions were the most common 
type of adverse event (AE). All were mild or moderate and resolved within a few days. 
Participants who received 30 µg ID had a higher rate of erythema and pruritus than other groups, 
and participants who received 300 µg with adjuvant IM had a higher rate of injection site pain 
than other groups. Other systemic AEs were also observed. Participants dosed with 30 µg ID had 
an increased rate of nausea, fatigue, headache, and myalgia relative to the control group, but 
participants dosed with 300 µg IM (with and without adjuvant) had only a slight increase in 
nausea relative to the control group. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 14 of 47 
All groups that received NDV-3 displayed an increase in serum and vaginal mucosal IgG and 
IgA1 titers against rAls3 after vaccination, relative to the control group. Those receiving a 
300-µg IM dose with AlOH adjuvant had serum anti-Als3 IgG and IgA titers that were on 
average 2-3-fold higher than those that received the 300-µg IM dose without AlOH adjuvant. An 
opsonophagocytic killing assay, which is typically use to evaluate bacterial vaccines but is also 
relevant for fungal vaccines, showed a clear association between serum anti-rAls3 antibody titer 
level and C albicans killing. These data demonstrate that the anti-rAls3 antibodies can direct an 
immune response against C albicans and thus the vaccine with the AlOH adjuvant is the 
preferred formulation for further study.   
An ELISpot assay of harvested PBMCs showed that for the groups dosed with 300 µg IM (with 
or without adjuvant), IFN-γ signal was higher at Day 7 than in the group dosed with 30 µg ID. 
Signals were similar between these three groups at Days 14 and 90. Signal for IL-17A in the 
300-µg IM groups (both with and without adjuvant) peaked at Day 7 and declined through 
Days 14 and 90. For the 30-µg ID group, IL-17A signal was lower than the 300-µg groups but 
more persistent through the duration of the study. 
The Phase 1b/2a study was designed to directly compare NDV-3 and NDV-3A for safety and 
immunogenicity and to evaluate NDV-3A for efficacy in reducing recurrences of vulvovaginal 
candidiasis (VVC) in women with recurrent infection. This study enrolled 188 women with 
recurrent VVC, all of whom have completed the study. Inclusion criteria required that all 
participants have a documented history of recurrent VVC and present with an active vaginal 
infection that is positive for C albicans. Final results show that 1) NDV-3 and NDV-3A are not 
substantially different for safety and immunogenicity, 2) NDV-3A is safe and induces a robust 
immune response in women with recurrent VVC, similar to what was seen in healthy women 
receiving NDV-3, 3) there were no serious AEs associated with administration of NDV-3 or 
NDV-3A, and 4) at 12 months post-vaccination of women with RVVC 42% who received 
NDV-3A were recurrence free whereas only 22% of placebo recipients were recurrence free. 
This translates to a point estimate of efficacy of approximately 30% (p = 0.029). 
 
Summary of Relevant Clinical Studies of Other Vaccines 
Aside from the studies described above for NDV-3 and NDV-3A, only one other effort was 
made in the past 28 years to evaluate a vaccine targeting a fungal pathogen in a 
placebo-controlled clinical study, that being a Phase 1 study by Pevion Biotech AG (Ittigen, 
Switzerland) of their vaccine candidate containing recombinant secreted aspartyl proteinase 2 
conjugated to an influenza virosome. The vaccine was shown to be safe but only mildly 
immunogenic following intravaginal administration. 
Over 20 different vaccine antigens targeting S aureus have been evaluated in placebo-controlled 
Phase 1-3 clinical studies.6 All were safe and immunogenic in Phase 1 studies. Vaccine 
candidates that advanced into Phase 2/3 studies are as follows: 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 15 of 47 
• Nabi evaluated a bivalent polysaccharide-protein conjugate vaccine based on serotypes 5 
and 8 in patients undergoing chronic hemodialysis. The vaccine induced a robust immune 
response that endured for > 1 year, and trended toward but did not reach statistical 
significance in reducing invasive infection.8,9 
• Inhibitex evaluated passive protection using antibody to clumping factor A in patients 
with established staphylococcemia. While antibody levels were durable, there was a trend 
toward but no statistically significant reduction in the risk of invasive infection.10 
• Merck evaluated a recombinant iron surface determinant B protein in cardiothoracic 
sternotomy patients.  While the antibody response was evident, the vaccine was 
potentially associated with serious post-operative complications.11,12 Data from other 
studies suggests that this safety issue may be specific to this vaccine antigen and/or 
patient population.   
• Pfizer is currently evaluating a quadrivalent vaccine (polysaccharide-protein conjugates 
for serotypes 5 and 8 plus recombinant clumping factor A and manganese transporter C 
proteins in a Phase 2/3 study in patients having elective posterior instrumented lumbar 
spinal fusion procedure. Results have not been reported yet though earlier studies showed 
the vaccine to be safe and immunogenic.13 
In contrast to this study, which will target mucocutaneous Candida and S aureus infections, the 
above studies were all targeting patients at risk of invasive S aureus infection. 
 
Rationale 
This exploratory study is designed to evaluate the immunological and safety response to 
NDV-3A in 20 AD-HIES patients and 20 healthy control participants. 
Autosomal-dominant hyper-IgE syndrome (AD-HIES, also referred to as Job’s syndrome) results 
from a dominant-negative mutation in STAT3.14 This condition causes an impairment of IL-17 
production by T-lymphocytes. Patients with AD-HIES are prone to mucocutaneous infection 
with both Candida and Staphylococcus. There is a large cohort of AD-HIES patients who are 
enrolled in a NIAID-sponsored natural history study at the NIH Clinical Center (CC). S aureus 
and C albicans are two pathogens of great concern to this patient population. Mucocutaneous 
infections are quite frequent and are typically controlled with chronic antibiotics and antifungals. 
However, resistance to standard antibiotics and antifungals is a growing problem. The potential 
of immunological intervention with a vaccine, particularly with one that has been shown to affect 
C albicans as well as S aureus disease, is very compelling. 
One of the major mechanisms of action of the NDV-3A vaccine is the stimulation of a Th17 
response by T-cells. Therefore, this vaccine could potentially protect AD-HIES patients against 
both of these mucocutaneous infections either by inducing protective antibodies or by boosting 
their impaired Th17 response. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 16 of 47 
There are many novel aspects to this study:  
• This study is the first to look at vaccine immunotherapy in people with AD-HIES. 
• There are no fungal vaccines approved for human use; NDV-3A is the only fungal 
vaccine in clinical development in the world. 
• NDV-3A is the only “cross-kingdom” vaccine, offering protection against both a fungal 
and a bacterial pathogen in preclinical studies, to enter clinical development. 
• NDV-3A has the potential to target critical healthcare-associated infections, including 
methicillin-resistant S aureus and fluconazole-resistant C albicans; there are no vaccines 
licensed or any other vaccines in clinical development to address such infections. 
• The data obtained from this study may direct future exploration of T-cell–activating 
adjuvants. 
2 Study Objectives 
 
Primary Objective 
To assess anti-rAls3 antibody titers in response to the study vaccine 14 days after vaccination. 
 
Secondary Objectives 
1. To evaluate the safety of the study vaccine in adults with AD-HIES. 
2. To assess anti-rAls3 antibody titers in response to the study vaccine 6 months after 
vaccination. 
 
Exploratory Objectives 
1. To determine the number and severity of Candida/Staphylococcus infections after 
vaccination compared to the historical pattern for each individual. 
2. To assess changes in Candida sp and S aureus colonization for pre- versus 
post-vaccination samples from skin, the oral, vaginal, and nasal (S aureus only) mucus 
and stool samples. 
3. To assess the level of Candida killing by mucosal secretions and the level of protective 
immune factors in mucosal secretions at pre-defined time points before and after 
vaccination. 
4. To assess RNA transcriptome changes 24 hours and 2 weeks after vaccination. 
5. To assess inflammatory markers and immunophenotypic changes in serum and PBMCs 
before and 2 weeks and 6 months post-vaccination, with specific interest in changes in 
IL-17A and IFN-γ expression. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 17 of 47 
3 Study Design 
 
Description of the Study Design 
This is an open-label, single-dose study to assess the safety, tolerability, and immunological and 
microbiological response to the NDV-3A vaccine. Twenty healthy adult volunteers and 20 adults 
with AD-HIES will be enrolled for this study. 
Study personnel will contact participants by telephone at Days 30, 60, 90, 120, and 150 
post-vaccination to assess any potential AEs and to conduct a concomitant medication review. 
Participants will return to the NIH CC for in-person safety assessments at 1 day, 2 days, 14 days, 
and 6 months post-vaccination. Additional unscheduled visits will be arranged as needed for 
evaluation and treatment of underlying conditions. All visits will include a physical exam; 
collection of blood, mucosal, skin, and stool samples; assessment of any injection site reactions; 
assessments of any potential AEs; and concomitant medication review. Blood samples will be 
processed to obtain serum and PBMCs for evaluation of immune response to the vaccine. 
Mucosal, skin, and stool samples collected will be evaluated for microbiological culture and 
PCR evidence of colonization by Candida sp and S aureus. 
 
Study Endpoints 
 
Primary Endpoint 
Percent of each group with at least a four-fold increase in anti-rAls3 antibody titer 2 weeks after 
vaccination. 
 
Secondary Endpoints 
1. Frequency of injection site and systemic AEs in AD-HIES affected patients and healthy 
volunteers.  
2. Anti-rAls3 antibody titers at 6 months after vaccination in patients with AD-HIES and 
healthy volunteers. 
 
Exploratory Endpoints 
1. Decrease in the number of S aureus and Candida sp infections in patients compared to 
historical infections in the 6 months prior to vaccination. 
2. Improved eczema in AD-HIES patients during the 6 months post-vaccination as 
evaluated with a SCORing Atopic Dermatitis (SCORAD) eczema severity score.   
3. Decrease in the colonization with S aureus and Candida sp for pre- versus 
post-vaccination samples from skin, the oral, vaginal, and nasal (S aureus only) mucus 
and stool samples. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 18 of 47 
4. Improved Candida sp killing by mucosal secretions and the level of protective immune 
factors in mucosal secretions at pre-defined time points before and after vaccination. 
5. Inflammatory and immunophenotypic changes at 1 day, 2 weeks and 6 months 
post-vaccination as assessed using RNAseq, extended flow cytometry and serum 
inflammatory markers, with specific interest in the IFNgamma and IL-17A responses 
4 Study Population 
 
Recruitment Plan 
Adults with AD-HIES (n = 20) will be co-enrolled in NIAID protocol 00-I-0159, “Natural 
History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection 
Syndrome (HIES).”  
Adult healthy volunteers (n = 20) will be recruited through the NIH Clinical Research Volunteer 
Program. The healthy volunteers will be recruited once AD-HIES volunteers are identified so 
they can be age matched within 5 years and gender matched, when possible.  
Recruitment of NIH employees: NIH employees and members of their immediate families may 
participate in this protocol. We will follow the Guidelines for the Inclusion of Employees in NIH 
Research Studies and will give each employee a copy of the “NIH Information Sheet on 
Employee Research Participation.” 
For NIH employees: 
• NIH staff may be a vulnerable class of participants. 
• Neither participation nor refusal to participate will have an effect, either beneficial or 
adverse, on the participant’s employment or work situation. 
• The NIH information sheet regarding NIH employee research participation will be 
distributed to all potential subjects who are NIH employees. 
• The employee subject’s privacy and confidentiality will be preserved in accordance with 
NIH CC and NIAID policies, which define the scope and limitations of the protections. 
• For NIH employee subjects, consent will be obtained by an individual independent of the 
employee’s team. Those in a supervisory position to any employee and co-workers of the 
employee will not obtain consent. 
• The importance of maintaining confidentiality when obtaining potentially sensitive and 
private information from co-workers or subordinates will be reviewed with the study staff 
at least annually and more often if warranted. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 19 of 47 
 
Subject Inclusion Criteria 
1. Age 18-55 years. 
2. For healthy volunteers: in general good health, without significant medical illness, 
physical exam findings, or significant laboratory abnormalities as determined by the 
investigator. 
3. For participants with AD-HIES: confirmation of diagnosis with a STAT3 mutation. 
4. Participants who can get pregnant must be willing to use an acceptable form of 
contraception for the duration of participation and have a negative pregnancy test at 
screening. 
5. Agree to allow storage of biological samples for future research. 
Contraception: The effects of the NDV-3A on the developing human fetus are unknown. For 
this reason, study participants must agree to use adequate contraception when engaging in sexual 
activities that can result in pregnancy. Acceptable forms of contraception are the following: 
• Intrauterine device (IUD) or equivalent. 
• Hormonal contraceptives (eg, consistent, timely and continuous use of contraceptive pill, 
patch, ring, implant, or injection that has reached full efficacy prior to dosing). If the 
participant uses a contraceptive pill, patch, or ring, then a barrier method 
(eg, male/female condom, cap, or diaphragm plus spermicide) must also be used at the 
time of potentially reproductive sexual activity. 
• Be in a stable, long-term monogamous relationship, per assessment of the principal 
investigator (PI), with a partner that does not pose any potential pregnancy risk, eg, has 
undergone a vasectomy at least 6 months prior to dose of study agent or is of the same 
sex as the patient. 
• Have had a hysterectomy and/or a bilateral tubal ligation or both ovaries removed. 
Adequate contraception must be used consistently, beginning 28 days before administration of 
the vaccine and lasting for the duration of study participation. Participants of childbearing 
potential must have a negative pregnancy test result before they receive the NDV-3A vaccine. 
During the course of the study, if a participant becomes pregnant or suspects they are pregnant, 
then they should inform the study staff and their primary care physician immediately. 
 
Subject Exclusion Criteria 
1. Has a history of allergic response or other serious reaction to aluminum and/or yeast 
products. 
2. Has a history of clinically significant allergy including anaphylaxis or other serious 
reaction to food, vaccines, or other drugs, that in the opinion of the investigator, might 
put the participant at undue risk.  

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 20 of 47 
3. Has an active infection (such as S aureus abscess, pneumonia, acute Candida 
mucocutaneous infection). Baseline state of chronic infections will be considered by the 
PI (eg, chronic Pseudomonas infection in lung). 
4. Has an active infection with hepatitis B, hepatitis C, or HIV.  
5. Has received or is planning to receive any investigational drug, investigational vaccine, 
or investigational device within four weeks prior to vaccination, or at any other time 
during their participation in the study. 
6. Has received or is planning to receive any other live vaccine within three weeks before 
vaccination or for three weeks after vaccination. 
7. Self-reported current alcohol abuse or addiction. 
8. Self-reported current illicit drug abuse or addiction, or drug screen positive for illicit 
drugs.   
9. Current or planned use, within 3 weeks before vaccination, of any medications or 
treatments that may alter immune responses to the study vaccine (eg, immunosuppressive 
medications including systemic corticosteroids, cyclosporine, tacrolimus, cytotoxic 
drugs, Bacillus Calmette-Guerin, monoclonal antibodies, or radiation therapy). Topical, 
intranasal, or inhaled immunosuppressants such as corticosteroids will be allowed.  
10. Current or planned use within 2 weeks before vaccination of immune globulin 
replacement.  
11. Has any of the following laboratory abnormalities at the screening visit: 
a. Alanine transaminase (ALT), aspartate transaminase (AST), and/or alkaline 
phosphatase (ALP) > 1.5 times the upper limit of normal (ULN). 
b. Total bilirubin level > 1.5 times the ULN 
c. Serum creatinine level > 1.5 times the ULN 
d. Absolute neutrophil count < 750 cells/µL 
e. Hemoglobin < 9 mg/dL 
f. Platelet count < 100,000 
12. Refusal or inability to comply with study procedures to the extent that it is potentially 
harmful to the participant or to the integrity of the study data. 
13. Has donated blood/plasma within four weeks before vaccination.  
14. Is pregnant or breastfeeding, or intends to become pregnant over the course of the study. 
15. Is unable to commit to the follow-up visits and or has unreliable access to a telephone for 
follow-up contacts, either by self-admission (self-reporting) or in the opinion of the 
investigator. 
16. Any other condition the investigator believes would interfere with the participant’s ability 
to provide informed consent, comply with study instructions, or that might confound the 
interpretation of the study results or put the participant at undue risk. 
Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on 
observational studies or those evaluating the use of a licensed medication. Study staff should be 
notified of co-enrollment as it may require the approval of the PI. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 21 of 47 
 
Justification for Exclusion of Special Populations 
 
Exclusion of women 
Pregnancy: Pregnant women are excluded from this study because the effects of the NDV-3A 
vaccine on the developing human fetus are unknown with respect to the potential for teratogenic 
or abortifacient effects. 
Breastfeeding: Because there is an unknown but potential risk for AEs in nursing infants 
secondary to treatment of the mother with the NDV-3A vaccine, potential participants who are 
breastfeeding are excluded from this study. 
 
Exclusion of minors 
Because there are insufficient data regarding dosing or AEs available in adults to judge the 
potential risk in minors, minors are excluded from this study. 
5 Study Agent/Interventions 
 
Disposition and Dispensation 
Study agent will be distributed via the NIH pharmacy according to standard pharmacy 
procedures. 
 
Formulation, Packaging, and Labeling 
An example of the label that will be on all vials appears below. 
 
 
NDV-3A Finished Drug Product 
[600 µg Als3/mL, 1.0mg Al/mL, 0.5 mL/dose] 
BPR No.:BPR-1231-00           Lot2002   
Contents: 0.7 + 0.1 mL           STORE 2-8°C 
Caution: New Drug - Limited by Federal  
Law to Investigational Use.  
Date of Mfg.: 20May2016 
Manufactured by: WRAIR, Silver Spring, MD 20910 
For NovaDigm Therapeutics Inc. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 22 of 47 
 
Study Agent Storage and Stability 
The NDV-3A vaccine will be stored at the NIH pharmacy at 2°C-8°C. Once put into the syringe, 
the vaccine can be held at room temperature for up to 8 hours. 
 
Preparation, Administration, and Dosage of Study Agent 
The single-dose, 2-mL glass vaccine vials contain 0.7 + 0.1 mL of vaccine, which is 
600-µg rAls3/mL formulated with 1.0-mg Al/mL as AlOH, in 10-mM sodium phosphate, 
154-mM sodium chloride, pH 6.5. The vials will be labeled and stored for use in this study. 
Participants will receive a single dose of 0.5 mL (300 µg of rAls3), administered via IM 
injection. The 300-µg dose has been administered to 201 patients. This dose elicited a robust 
immune response in adults and did not produce any serious vaccine-attributable AEs. 
 
Study Product Accountability Procedures 
The NIH pharmacy will maintain accurate accountability records. Instructions and the required 
accountability documentation will be provided to the study pharmacist. When the study is 
completed, copies of the study drug accountability records will be returned to the sponsor, and 
the originals maintained at the study site. Copies of the drug accountability records must be 
maintained with the rest of the documentation for the study. All unused study agent must be 
disposed of upon authorization by the sponsor. All records regarding the disposition of study 
drug must be available for inspection by the study monitors and regulatory authorities. 
 
Assessment of Subject Compliance with Study Agent 
The study team will administer a single dose of the NDV-3A vaccine to each participant. 
Ordered doses of NDV-3A will be documented in the CC Clinical Research Information System 
(CRIS). The Clinical Research Information Management System of the NIAID (CRIMSON) will 
be the primary source for dose administration. The dose administration will also be documented 
in CRIS. 
 
Concomitant Medications and Procedures 
All concomitant prescription and nonprescription (including over-the-counter, herbal 
supplements, and vitamins) medications taken during study participation will be recorded. For 
this protocol, a prescription medication is defined as a medication that can be prescribed only by 
a properly authorized/licensed clinician. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 23 of 47 
 
Prohibited Medications and Procedures 
Use of any medications or treatments that may alter immune responses to the study vaccine 
throughout the study (eg, cyclosporine, tacrolimus, cytotoxic drugs, Bacillus Calmette-Guerin, 
monoclonal antibodies, or radiation therapy) is prohibited. Participants may start using these 
drugs after study participation has ended. 
Treatment with antibiotics or antifungals will not be permitted unless discussed with and 
approved by the PI. 
6 Study Schedule and Procedures 
All visits will take place at the NIH CC. The study schedule is presented in tabular form in 
Appendix A. Blood draw volumes are presented in Appendix B. 
 
Screening (Day −28 to baseline) 
Informed consent will be obtained before any study procedures begin.  
Participants with AD-HIES will be recruited from NIAID protocol 00-I-0159. The eligibility 
criteria, including medical history and physical examination findings, will be evaluated from the 
immunologic, genetic, and/or initial evaluation conducted as part of the referring protocol. 
Laboratory, history, and exam findings to fulfill eligibility criteria must be collected within 
28 days before enrollment in this protocol. If findings are not available from the referring 
protocol within that timeframe, then physical exam, medical history, sample collection, and 
pregnancy test will be conducted under this protocol. 
Healthy volunteers will undergo the following screening procedures at the screening visit: 
1. Physical exam with vital signs 
2. Medical history and documentation of concomitant medications 
3. Urine drug screening 
4. Collection of blood for hepatitis B (antigen and antibody), hepatitis C antibody, and HIV 
antibody testing; acute, hepatic, and mineral panels; prothrombin/partial thromboplastin 
time; complete blood count with differential; lymphocyte flow cytometry (BD Multitest 
6-Color TBNK Reagent [BD Biosciences, Franklin Lakes, NJ, USA]); and serum 
immunoglobin quantitation. 
5. Serum pregnancy test for participants who are able to become pregnant 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 24 of 47 
 
Baseline Visits (Days –3 to 0) 
After eligibility is confirmed, all participants will return to the NIH CC for two separate baseline 
visits. The first baseline will be done 1 to 3 days before vaccination, and the second will be done 
the day of vaccination (Day 0) before administration of the study vaccine.  
At both baseline visits, blood will be collected for harvesting of PBMCs for CHI pre-vaccination 
analysis: cryopreservation, potential genetic testing, whole transcriptome sequencing, multiplex 
analysis of inflammatory markers, and immunophenotyping. 
Participants of childbearing potential will have a pregnancy test on Day 0. The test must be 
negative in order for the participant to receive the vaccine. 
The following procedures will be conducted at only one of the baseline visits, and will be 
scheduled depending on the investigators’ and participant’s convenience: 
1. Physical exam with vital signs. 
2. Detailed history of Staphylococcus and Candida infections requiring treatment 
(eg, additional medications, drainage) in the last 6 months. 
3. SCORAD eczema scoring assessment (for participants with AD-HIES only). 
4. Collection of blood for research laboratory evaluations that may include but are not 
limited to ELISA for anti-rAls3 IgG and IgA1. 
5. Collection of saliva and/or vaginal secretions for research evaluations: ELISA for 
anti-rAls3 IgG and IgA1; in vitro killing assay of C albicans. Vaginal secretion 
collection is optional.   
6. Collection of stool, skin swab, and oral, nasal, and vaginal mucus may be collected for 
research evaluations: culture and PCR for Candida sp and S aureus; microbiome 
analysis (stool and oral and vaginal mucus only). Vaginal mucus collection and stool 
samples are optional.  
 
Visit for Vaccination (Days 0 to 2) 
After the baseline evaluations have been conducted on Day 0, participants will receive a single 
dose of the NDV-3A vaccine (0.5 mL, 300-µg rAls3, 0.5-mg Al as AlOH, in PBS) via IM 
injection. The study team will observe the participant for 30 minutes post-injection to monitor 
for potential allergic or anaphylactic reactions. The study team will provide the participant with a 
14-day diary card and instructions to record post-injection reactions. Participants will return to 
the NIH CC for 2 days after the injection (Day 1 and 2) for physical exam with vital signs and 
assessment of AEs and injection site. They will return the diary card at the Day 14 
post-vaccination visit. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 25 of 47 
On Day 1 only, blood will be collected for storage of PBMCs, serum, and RNA. These samples 
will be saved for analysis of acute inflammatory responses to the vaccination.  
The first 3 participants with AD-HIES will be scheduled for their vaccination visit at least 
48 hours apart from each other so there is no overlap. This will allow the study team to monitor 
for acute AEs in this population before administering NDV-3A to the other AD-HIES 
participants. 
 
Follow-up Visits 
Participants will return to the NIH CC for in-person follow-up visits at Days 14 (± 3 days) and 
180 (± 14 days) Participants will undergo the following procedures at each visit: 
1. Physical exam with vital signs. 
2. Review of concomitant medications. 
3. Assessment of AEs and injection site. 
4. Review of diary card (Day 14 only). 
5. SCORAD as an eczema severity score (for participants with AD-HIES only). 
6. Detailed history of Staphylococcus and Candida infections requiring treatment 
(eg, additional medications, drainage) since prior visit. 
7. Collection of blood for ELISA for anti-rAls3 IgG and IgA1 and potential other research 
laboratory evaluations. 
8. Collection of saliva and/or vaginal secretions for research evaluations: ELISA for 
anti-rAls3 IgG and IgA1; in vitro killing assay of C albicans. Vaginal secretion collection 
is optional.  
9. Collection of stool, skin swab, and oral, nasal, and vaginal mucus may be collected for 
research evaluations: culture and PCR for Candida sp and S aureus; microbiome analysis 
(stool and oral and vaginal mucus only). Vaginal secretion collection and stool samples 
are optional.   
10. Pregnancy test (Day 14 only). 
11. Harvesting of PBMCs for research laboratory evaluations to be performed by CHI: 
a. Cryopreservation of PBMCs after vaccination 
b. Collection of PBMC DNA for potential genetic testing 
c. Whole transcriptome sequencing of PBMCs 
d. Multiplex assays for inflammatory markers 
e. Flow cytometry of PBMCs for immunophenotyping and activation status after 
vaccination 
The participant will be given a memory aid on Day 14 to take home for tracking suspected 
vaccine-related AEs for the remainder of the study. This memory aid will facilitate accurate AE 
assessment at the monthly phone calls (see below).  

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 26 of 47 
Participants will be strongly encouraged to return to the NIH CC for a follow-up visit on Day 42 
(± 7 days), although this visit is optional. AEs will be assessed and serum will be collected for 
ELISA for anti-rAls3 IgG and IgA1. If traveling to the NIH CC is inconvenient for the 
participant but they still want to provide samples for this time point, then blood can be drawn 
from their doctor or local laboratory (eg, Quest Diagnostics) and shipped to the study team. 
At Days 30, 60, 90, 120, and 150 (± 3 days), the study team will contact the participant by phone 
to assess AEs, conduct a concomitant medication review, and assess any infections the 
participant has experienced in the interim. 
Participants and investigators may schedule additional in-person visits to the NIH CC during the 
6-month post-vaccination period for evaluation and care of suspected vaccine-related AEs. 
Study participation ends after the Day 180 visit.  
 
Early Termination Visit 
All effort will be made to conduct an early termination visit for participants who withdraw from 
the study. This visit will include all of the procedures performed at the normal end-of-study visit. 
 
Pregnancy and Follow-up Visit 
If a participant becomes pregnant during the course of the study after they receive the vaccine, 
then they may continue follow-up visits as normal. Blood for research evaluations will not be 
collected. The study team will ask the participant to notify them of the pregnancy outcome 
including the weeks of gestation, and pregnancy and birth complications. 
7 Potential Risks and Benefits 
 
Potential Risks 
NDV-3A vaccine: The precursor of the study vaccine (NDV-3) has been given to 109 healthy 
adults and the study vaccine (NDV-3A) has been given to 89 adult women with recurrent VVC 
in 3 previous clinical trials via IM injection at the same dose to be used in this study. In all 
studies, the vaccine was well tolerated, and the most common AEs were mild injection site 
complaints (eg, erythema, induration, pain, and swelling). Systemic AEs included diarrhea, 
nausea, fatigue, myalgia, and headache. All AEs resolved on their own without sequelae.  
The study vaccine was also administered at a lower dose level (30-µg rAls3) in 2 clinical studies. 
Fifteen subjects received an IM dose with AlOH and experienced similar local and systemic 
reactions as seen with the 300-µg dose. The vaccine at 30-µg rAls3 without AlOH was also 
administered ID to 40 subjects, which resulted in a higher incidence of local site and systemic 
AEs compared to IM injection. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 27 of 47 
There may be additional risks to NDV-3A that are currently unknown. 
Blood draw: The risks of drawing blood include pain, bruising, bleeding, and, rarely, fainting or 
infection. The amount of blood drawn for research purposes will be within the limits allowed for 
adult research subjects by the NIH CC (Medical Administrative Policy 95-9, Guidelines for 
Limits of Blood Drawn for Research Purposes in the Clinical Center: http://cc-
internal.cc.nih.gov/policies/PDF/M95-9.pdf). 
Genetic Testing: Genetic testing, which may include whole genome, transcriptome, and/or 
exome sequencing, may be done on collected specimens in an effort to identify genetic 
components of these diseases and syndromes. Results of genetic testing may have psychological 
implications for participants such as revelations regarding future health risks, incurable 
conditions, and/or information contradictory to stated biological relationships. Genetics 
counseling and advice is available from the NIH to help participants with the implications of 
findings, where appropriate. 
Further testing may be performed on gene variants that are discovered, principally those that are 
the focus of the main objective of this protocol that have unknown functions or that are believed 
to have health implications. Depending on how much information is known about a particular 
gene, such testing may take several years to complete. The results of this testing may require 
examination in other subjects with immune disorders or may require additional tests to be 
performed on relatives, particularly parents and siblings. As new information becomes available, 
existing sequencing data may require reexamination. Genetic counseling and clinical genetics 
consultation is available at the NIH CC to help patients with the implications of findings, where 
appropriate.  
Following genetic testing, the data will be shared in a controlled-access public database for other 
investigators to benefit from it (eg, dbGaP, the Database of Genotypes and Phenotypes). 
However no personal, identifiable information will be shared in this process as the results will be 
identified only by a code. 
Vaginal secretion collection: Vaginal secretions will be collected using a menstrual cup. 
Participants may experience pressure as the menstrual cup is inserted into the vaginal cavity. The 
participant should not feel any discomfort during the secretion collection. The test is usually not 
painful. There is a risk of dislodging an IUD with the menstrual cup, so vaginal fluid collection 
will NOT be done in participants with IUDs. There is also a risk of toxic shock syndrome when 
the menstrual cup is left in the vaginal cavity for more than 12 hours. Participants will be 
instructed to remove the menstrual cup after 1 to 2 hours. 
Collection of saliva, skin swab, stool, and oral/nasal/vaginal mucus: Collection of these 
samples may cause mild discomfort or irritation but there are otherwise no risks associated with 
collection of these samples. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 28 of 47 
 
Potential Benefits 
Participants may not directly benefit from involvement in this study. The information gathered in 
this study may improve the investigators’ understanding of the safety, tolerability, and 
immunogenicity of the NDV-3A vaccine, and its potential use as a prophylactic against infection 
from Candida sp and S aureus. 
8 Research Use of Stored Human Samples, Specimens, or Data 
Intended Use: Samples and data collected under this protocol may be used to study the safety 
and immunogenicity of the NDV-3A vaccine. Genetic testing may be performed. A separate 
signed informed consent document will be obtained for any other research not described in this 
protocol. 
Storage: Access to stored samples will be limited using either a locked room or a locked freezer. 
Samples and data will be stored using codes assigned by the investigators. Data will be kept in 
password-protected computers. Only investigators will have access to the samples and data.  
Tracking: Samples and data will be tracked using a code that only the study team can trace back 
to the participants. Clinical data will be entered into CRIMSON. 
Disposition at the Completion of the Protocol: 
In the future, other investigators (both at NIH and outside) may wish to study these samples 
and/or data. IRB approval must be sought prior to any sharing of any samples and/or data. Any 
clinical information shared about the sample would similarly require prior IRB approval. The 
research use of stored, unlinked, or unidentified samples or data may be exempt from the need 
for prospective IRB review and approval. Exemption requests will be submitted in writing to the 
NIH Office of Human Subjects Research Protections, which is authorized to determine whether a 
research activity is exempt. 
At the time of protocol termination, samples will either be destroyed, or after IRB approval, 
transferred to another existing protocol. Data will be archived by the study team in compliance 
with requirements for retention of research records; alternatively, after IRB and study sponsor 
approval, the data may be either destroyed or transferred to another repository. 
Reporting the Loss or Destruction of Samples/Specimens/Data to the IRB: 
Any loss or unanticipated destruction of samples (for example, as the result of freezer 
malfunction) or data (for example, misplacing a printout of data with identifiers) that meets the 
definition of protocol deviation or unanticipated problem (UP) and/or compromises the scientific 
integrity of the data collected for the study will be reported to the NIAID IRB.  

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 29 of 47 
Participants may decide at any point not to have their samples stored. In this case, the PI will 
destroy all known remaining samples and report what was done to both the participant and to the 
IRB. This decision will not affect the participant’s involvement in this protocol or any other 
protocols at NIH. 
9 Data Sharing Plan 
Human data generated in this study will be shared for future research as follows: 
• Identified data in the Biomedical Translational Research Information System (BTRIS, 
automatic for activities in the NIH CC). 
• Data sharing may be complicated or limited in certain cases by contractual obligations or 
agreements with outside collaborators, such as Cooperative Research and Development 
Agreements, Clinical Trial Agreements, other restraints, etc.  
Data will be shared through the following means: 
• BTRIS (automatic for activities in the CC). 
• Approved outside collaborators under appropriate individual agreements. 
• Publication and/or public presentations. 
Data will be shared before publication/at the time of publication or shortly thereafter. 
10 Remuneration Plan for Participants 
Participants will receive compensation as follows: 
Visit 
Compensation 
Screening 
$40 
First baseline (Day −3 to −1) 
$100 
Second baseline/vaccine administration (Day 0) 
$100 
Day 1 
$60 
Day 2 
$30 
Day 14 
$170 
Day 42 
$50 
Day 180 
$130 
Maximum total 
$680 
 
Because collections of vaginal mucus and secretions are optional, participants will receive an 
additional $20 per applicable visit if they provide these samples. These samples are collected at 
one of the baseline visits and Days 14 and 180, so the maximum additional compensation is $60. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 30 of 47 
11 Assessment of Safety 
 
Definitions 
Adverse Event: An AE is any untoward or unfavorable medical occurrence in a human research 
participant, including any abnormal sign (eg, abnormal physical exam or laboratory finding), 
symptom, or disease, temporally associated with the participant’s participation in the research, 
whether or not considered related to the research. 
Adverse Reaction (AR): An AE that is caused by an investigational agent (drug or biologic). 
Suspected Adverse Reaction (SAR): An AE for which there is a reasonable possibility that the 
investigational agent caused the AE. “Reasonable possibility” means that there is evidence to 
suggest a causal relationship between the drug and the AE. An SAR implies a lesser degree of 
certainty about causality than AR, which implies a high degree of certainty. 
Serious Adverse Event: An SAE is an AE that results in one or more of the following 
outcomes: 
• death 
• a life-threatening event (places the participant at immediate risk of death from the event 
as it occurred) 
• an inpatient hospitalization or prolongation of an existing hospitalization 
• a persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
• a congenital anomaly/birth defect 
• a medically important event* 
*Medical and scientific judgment should be exercised in deciding events that may not be 
immediately life threatening or result in death or hospitalization but may jeopardize the 
participant or may require intervention to prevent one of the other outcomes listed above. 
Unexpected Adverse Event: An AE is unexpected if it is not listed in the Investigator’s 
Brochure or is not listed at the specificity or severity that has been observed. It is the 
responsibility of the Investigational New Drug (IND) sponsor to make this determination. 
Serious and Unexpected Suspected Adverse Reaction (SUSAR): A SUSAR is an SAR that is 
both serious and unexpected. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 31 of 47 
Unanticipated Problem (UP): Any incident, experience, or outcome that meets all three of the 
following criteria:  
1. unexpected in terms of nature, severity, or frequency in relation to 
a. the research risks that are described in the IRB-approved research protocol and 
informed consent document; Investigator’s Brochure or other study documents; and 
b. the characteristics of the subject population being studied 
2. related or possibly related to participation in the research 
3. suggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized. 
Serious Unanticipated Problem: A UP that meets the definition of an SAE or compromises the 
safety, welfare or rights of subjects or others. 
Unanticipated Problem that is not an Adverse Event (UPnonAE): A UP that does not fit the 
definition of an AE, but which may, in the opinion of the investigator, involve risk to the subject, 
affect others in the research study, or significantly impact the integrity of research data. Such 
events would be considered non-serious UPs. For example, we will report occurrences of 
breaches of confidentiality, accidental destruction of study records, or unaccounted-for study 
drug. 
Protocol Specified Events: Protocol specified events are AEs specified in the protocol that the 
PI, IND sponsor, or medical monitor would like to review in real time rather than weeks or 
months later when they would otherwise appear in various line listings. These events may or may 
not also be SAEs. 
 
Documenting, Recording, and Reporting Adverse Events 
All AEs occurring from the time the informed consent is signed through the final study visit will 
be documented, recorded, and reported. 
At each contact with the participant, information regarding AEs will be elicited by appropriate 
questioning and examinations and will be: 
• immediately documented in the participant’s medical record/source document 
• recorded in CRIMSON 
AND 
• reported as outlined below (eg, IND sponsor, IRB, and Food and Drug Administration 
[FDA]) 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 32 of 47 
If a diagnosis is clinically evident (or subsequently determined), then the diagnosis rather than 
the individual signs and symptoms or lab abnormalities will be recorded as the AE. 
A laboratory abnormality will not be reported as an AE if ALL of the following criteria are met: 
• It is no more than “Grade 1” or “Mild” per the protocol-specified toxicity table (or 
investigator assessment if not listed on the table); AND 
• It does NOT require an intervention (eg, discontinuation of treatment, dose 
reduction/delay, additional assessments, or treatment); AND 
• It is assessed by the PI as NOT related to the study agent(s); AND 
• It is assessed by the PI as NOT clinically significant (eg, the abnormal value does NOT 
suggest a disease or organ toxicity). 
All abnormal laboratory findings will be reviewed on a routine basis by the PI to identify 
potential safety signals. An abnormal lab not included on the toxicity table should be assessed in 
a similar fashion to the criteria above and per toxicity table guidelines “Instructions for Use.” 
 
Investigator Assessment of Adverse Events 
The investigator will assess all AEs with respect to seriousness (criteria listed above), severity 
(intensity or grade), and causality (relationship to study agent and relationship to research) 
according to the following guidelines. 
 
Severity 
The Investigator will grade the severity of each AE according to the “Division of Aids Table for 
Grading the Severity of Adult and Pediatric Adverse Events” Version 2.0, November 2014, 
which can be found at:  
http://rsc.tech-
res.com/document/safetyandpharmacovigilance/daids_ae_grading_table_v2_nov2014.pdf  
Some Grade 1 lab parameters on the DAIDS Toxicity Table (fibrinogen, potassium [low], uric 
acid [males only, elevated]) fall within the NIH lab reference range for normal values. These 
normal values will not be reported as Grade 1 AEs. The Grade 1 values for these tests will be 
reported as follows: 
• Fibrinogen: 100-176 mg/dL 
• Potassium (low): 3.0-3.3 mmol/L 
• Uric acid (males): 8.7-10.0 mg/dL 
• Magnesium (low): 0.60-0.65 mmol/L 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 33 of 47 
 
Causality 
Causality (likelihood that the event is caused by the study agent) will be assessed considering the 
factors listed under the following categories: 
Definitely Related 
• reasonable temporal relationship 
• follows a known response pattern 
• clear evidence to suggest a causal relationship 
• there is no alternative etiology 
Probably Related 
• reasonable temporal relationship 
• follows a suspected response pattern (based on similar agents) 
• no evidence of a more likely alternative etiology 
Possibly Related 
• reasonable temporal relationship 
• little evidence for a more likely alternative etiology 
Unlikely Related 
• does not have a reasonable temporal relationship 
OR 
• good evidence for a more likely alternative etiology 
Not Related 
• does not have a temporal relationship 
OR 
• definitely due to an alternative etiology 
Note: Other factors should also be considered for each causality category when appropriate. 
Causality assessment is based on available information at the time of the assessment of the AE. 
The investigator may revise the causality assessment as additional information becomes 
available. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 34 of 47 
 
Investigator Reporting Responsibilities to the Sponsor 
 
Adverse Events 
AE data will be submitted to the IND sponsor when requested for periodic safety assessments, 
review of IND annual reports, review of IND safety reports, and preparation of final study 
reports. 
 
Reactogenicity 
Specified solicited reactogenicity to vaccination will be evaluated per Table 1 below: 
Table 1 Evaluation of Vaccine Reactogencity 
Local Reaction to 
Injectable Product  
Mild (Grade 1)  
Moderate (Grade 2)  
Severe (Grade 3)  
Potentially Life 
Threatening  
(Grade 4)  
Erythema/Rednessa 
1.0-4.0 cm  
4.1-8.0 cm  
> 8.0 cm  
Necrosis or exfoliative 
dermatitis  
Pain  
Does not interfere 
with activity  
Repeated use of non-
narcotic pain reliever 
> 24 hours or 
interferes with activity  
Any use of narcotic 
pain reliever or 
prevents daily activity  
ER visit or 
hospitalization  
Tenderness  
Mild discomfort to 
touch  
Discomfort with 
movement  
Significant discomfort 
at rest  
ER visit or 
hospitalization  
Indurationb 
1.0-4.0 cm and does 
not interfere with 
activity  
4.1-8.0 cm or 
interferes with activity  
> 8.0 cm or prevents 
daily activity  
Necrosis (regardless of 
size of induration) 
Swellingb 
1.0-4.0 cm and does 
not interfere with 
activity  
4.1-8.0 cm or 
interferes with activity  
> 8.0 cm or prevents 
daily activity  
Necrosis (regardless of 
size of swelling) 
ER = emergency room. 
a 
In addition to grading the measure local reaction at the greatest single diameter, the measurement should be recorded as a 
continuous variable. 
b 
Induration/swelling should be evaluated and grated using the functional scale as well as the actual measurement. 
 
 
Serious Adverse Events 
All SAEs (regardless of relationship and whether or not they are also UPs) must be reported on 
the Safety Expedited Report Form (SERF) and sent to the Clinical Safety Office (CSO) by fax or 
e-mail attachment. Deaths and immediately life-threatening SAEs must be reported to the CSO 
within 1 business day after the site becomes aware of the event. All other SAEs must be reported 
within 3 business days of site awareness. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 35 of 47 
CSO CONTACT INFORMATION: 
Clinical Safety Office 
5705 Industry Lane 
Frederick, MD 21704 
Phone: 301-846-5301 
Fax: 301-846-6224 
E-mail: rchspsafety@mail.nih.gov  
SAEs that have not resolved by the end of the follow-up period are followed until final outcome 
is known. If it is not possible to obtain a final outcome for an SAE (eg, the participant is lost to 
follow-up), the reason a final outcome could not be obtained will be recorded by the investigator 
in CRIMSON and the SERF. 
SAEs that occur after the 6-month follow-up period that are reported to and are assessed by the 
investigator to be possibly, probably, or definitely related to study drug must be reported to the 
CSO. 
 
Unanticipated Problems 
UPs that are also AEs must be reported to the CSO by fax or e-mail attachment using the NIH 
Problem Report Form no later than 7 calendar days of site awareness of the event. UPs that are 
not AEs are not reported to the CSO. 
 
Pregnancy 
All pregnancies will be reported on the Pregnancy Notification/Outcome Form to the CSO 
within 1 business day from site awareness. 
Pregnancy outcome data (eg, delivery outcome, spontaneous or elective termination of the 
pregnancy) will be reported to the CSO within 3 business days of the site’s awareness. 
Although pregnancy itself is not an AE, events that meet SAE criteria during pregnancy, 
delivery, or in the neonate (eg, congenital anomaly/birth defect) are reportable on the SERF. 
In the event of pregnancy after administration of the vaccine, the following steps will be taken: 
• Continue the study visits, but blood for research evaluations will not be drawn. 
• Report to the SMC and/or the IRB. 
• Advise participant to notify the obstetrician of study participation and study agent 
exposure. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 36 of 47 
 
Investigator Reporting Procedures to the NIAID IRB 
 
Definitions 
Protocol Deviation: Any change, divergence, or departure from the IRB-approved study 
procedures in a research protocol. Protocol deviations are designated as serious or non-serious 
and further characterized as: 
1. Those that occur because a member of the research team deviates from the protocol. 
2. Those that are identified before they occur, but cannot be prevented. 
3. Those that are discovered after they occur. 
Serious Protocol Deviation: A deviation that meets the definition of an SAE or compromises 
the safety, welfare, or rights of subjects or others. 
Non-compliance: The failure to comply with applicable NIH Human Research Protections 
Program (HRPP) policies, IRB requirements, or regulatory requirements for the protection of 
human subjects. Non-compliance is further characterized as: 
1. Serious: non-compliance that: 
a. increases risks, or causes harm, to participants; 
b. decreases potential benefits to participants; 
c. compromises the integrity of the NIH HRPP; or 
d. invalidates the study data. 
2. Continuing: non-compliance that is recurring. 
3. Minor: non-compliance that is neither serious nor continuing. 
 
Expedited Reporting to the NIAID IRB 
Serious and non-serious UPs, deaths, serious deviations, and serious or continuing 
non-compliance will be reported within 7 calendar days of investigator awareness. SAEs that are 
possibly, probably, or definitely related to the research will be reported to the NIAID IRB within 
7 calendar days of investigator’s awareness, regardless of expectedness. 
 
Waiver of Reporting Anticipated Protocol Deviations, Expected UPnonAEs, and 
Deaths to the NIAID IRB 
Anticipated deviations in the conduct of the protocol will not be reported to the IRB unless they 
occur at a rate greater than anticipated by the study team. Deaths unrelated to any research 
procedures will be reported at the time of continuing review. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 37 of 47 
 
Annual Reporting to the NIAID IRB 
The following items will be reported to the NIAID IRB in summary at the time of continuing 
review: 
• Serious and non-serious UPs.  
• Expected SAEs that are possibly, probably, or definitely related to the research. 
• SAEs that are not related to the research. 
• All AEs  
• Serious and non-serious protocol deviations.  
• Serious, continuing, and minor non-compliance. 
• Any trends or events which in the opinion of the investigator should be reported. 
 
Sponsor’s Reporting Responsibilities 
SUSARs, as defined in Title 21 of the United States Code of Federal Regulations (CFR) 
Part 312.32 and determined by the IND sponsor, will be reported to FDA and all participating 
investigators as IND Safety Reports. 
The IND sponsor will also submit an IND Annual Report of the progress of the investigation to 
the FDA as defined in 21 CFR 312.33. 
 
Halting Rules for the Protocol 
Halting the study requires immediate discontinuation of study agent administered for all 
participants and suspension of enrollment until a decision is made whether or not to continue 
enrollment and study agent administration. 
The halting rules are: 
• 1 or more subjects experience the same or similar SAEs that are unexpected and possibly, 
probably, or definitely related to the study agent; 
OR 
• 2 or more of the same or similar AE in different subjects that are grade 3 or above and are 
unexpected and possibly, probably, or definitely related to the study agent; 
OR 
• any safety issue that the PI and/or the CSO determines should halt the study. 
The PI and/or CSO will determine if the study should be halted. In addition, the FDA, IRB, or 
SMC may halt the study at any time following review of any safety concerns. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 38 of 47 
 
Reporting a Study Halt 
If a halting rule is met, a description of the AE(s) or safety issue must be reported by the PI 
within 1 business day to the CSO, the IRB, the SMC, and NovaDigm by fax or email. 
 
Resumption of a Halted Study 
The IND sponsor, in collaboration with the PI and the SMC will determine if it is safe to resume 
the study. The PI will notify the IRB of the decision on resumption of the study. 
 
Withdrawal Criteria for an Individual Participant 
An individual participant will be withdrawn for any of the following: 
• An individual participant’s decision. (The investigator should attempt to determine the 
reason for the participant’s decision.) 
• Non-compliance with study procedures to the extent that it is potentially harmful to the 
participant or to the integrity of the study data. 
• A change in the participant’s baseline condition after enrollment but prior to vaccination 
so that the participant no longer meets the following exclusion criteria: 
o Has a history of clinically significant allergy including anaphylaxis or other serious 
reaction to food, vaccines, or other drugs, that in the opinion of the investigator, 
might put the participant at undue risk.  
o Has an active infection (such as S aureus abscess, pneumonia, or acute Candida 
mucocutaneous infection). Baseline state of chronic infections will be considered by 
the PI (eg, chronic Pseudomonas infection in lung).   
o Has received or planning to receive any other live vaccine within three weeks before 
vaccination or for three weeks after vaccination. 
o Has any of the following laboratory abnormalities: 
§ ALT, AST, and ALP > 3 times the ULN 
§ Total bilirubin level > 2.5 times the ULN 
§ Serum creatinine level > 2 times the ULN 
§ Absolute neutrophil count < 500 cells/µL 
§ Hemoglobin < 9 mg/dL 
§ Platelet count < 100,000 
• The investigator determines that continued participation in the study would not be in the 
best interest of the participant. 
 
Replacement of Withdrawn Participant 
Only withdrawn participants who have not yet received the study vaccine will be replaced.  

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 39 of 47 
 
Safety Oversight 
 
Safety Review and Communications Plan 
A Safety Review and Communications Plan (SRCP) has been developed for the protocol. The 
SRCP is an internal communications document between the PI and the CSO, which delineates 
the safety oversight responsibilities of the PI, the CSO, and other stakeholders. The SRCP also 
includes the overall plan for conducting periodic safety surveillance assessments. 
 
Sponsor Medical Monitor 
A medical monitor, representing the IND sponsor (OCRPRO), has been appointed for oversight 
of safety in this clinical study. The Sponsor Medical Monitor will be responsible for performing 
safety assessments as outlined in an SRCP. 
 
Safety Monitoring Committee 
An independent SMC consisting of three individuals will review the study prior to initiation and 
at a specified time agreed upon by the SMC. The SMC will focus on participant safety and will 
include subject matter experts. The independent experts do not have direct involvement in the 
conduct of the study and have no significant conflicts of interest as defined by NIAID policy. 
Before each SMC review, the PI will submit data as requested by the SMC. After each SMC 
review, a recommendation as to whether the study is to continue, be modified, or be terminated 
will be provided in a summary report. All SAEs, all UPs, and all IND Safety Reports will be 
reported by the PI to the SMC at the same time they are submitted to the IRB or IND sponsor. 
The SMC will be notified immediately if pausing or halting rules are met, and the SMC will 
provide a recommendation for continuation, modification, or termination of the study. The PI 
will submit the written SMC summary reports with recommendations to their IRB. 
12 Site Monitoring Plan 
According to the International Council on Harmonisation (ICH) E6(R1) Good Clinical Practice 
(GCP) guidelines (section 5.18) and 21 CFR 312.50, clinical protocols are required to be 
adequately monitored by the study sponsor. This study monitoring will be conducted according 
to the “NIAID Intramural Clinical Monitoring Guidelines.” Monitors under contract to 
OCRPRO/NIAID will visit the clinical research site to monitor aspects of the study in 
accordance with the appropriate regulations and the approved protocol. The objectives of a 
monitoring visit will be: 1) to verify the existence of signed informed consent documents and 
documentation of the consent process for each monitored participant; 2) to verify the prompt and 
accurate recording of all monitored data points, and prompt reporting of all SAEs; 3) to compare 
CRIMSON data abstracts with individual participants’ records and source documents 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 40 of 47 
(participants’ charts, laboratory analyses and test results, physicians’ progress notes, nurses’ 
notes, and any other relevant original subject information); and 4) to help ensure investigators 
are in compliance with the protocol. The monitors also will inspect the clinical site regulatory 
files to ensure that regulatory requirements (Office for Human Research Protections [OHRP]), 
FDA, and applicable guidelines (ICH GCP) are being followed. During the monitoring visits, the 
investigator (and/or designee) and other study personnel will be available to discuss the study 
progress and monitoring visit. 
The investigator (and/or designee) will make study documents (eg, consent forms, CRIMSON 
data abstracts) and pertinent hospital or clinical records readily available for inspection by the 
IRB, the FDA, the site monitors, and the NIAID staff for confirmation of the study data.  
A specific protocol monitoring plan will be discussed with the PI and study staff prior to 
enrollment. The plan will outline the frequency of monitoring visits based on such factors as 
study enrollment, data collection status, and regulatory obligations. 
13 Statistical Considerations 
 
Study Hypotheses 
NDV-3A will increase anti-Als3 antibody titers from baseline in AD-HIES patients as well as 
healthy volunteers. 
 
Sample Size Justification 
In this design, a positive response is a 4-fold increase in vaccine-specific IgG from baseline 
2 weeks post-vaccination. We assume that we are only interested in exploring NDV-3A further 
in AD-HIES patients if the response rate is higher than 45%. We will perform a single-arm 
2-stage design where there will be 0.9 probability of concluding NDV-3A has activity if the true 
response rate is 75% and where there will be probability 0.1 of concluding NDV-3A is active 
when in fact the true response rate is 45%. 
 
Description of the Analyses 
• Safety Analysis: Tables of the proportions of patients with AE’s and the grade of AE will 
be reported. 
• Immunogenicity Analysis: At the end of the study if 12 or more (out of 20) positive 
responses are observed the drug will have shown adequate activity to be considered for 
further investigation.  
 
Secondary Endpoints 
The following additional secondary endpoints will be examined:  

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 41 of 47 
1. Cellular response to vaccine as determined by IFN-γ and IL-17A production by PBMCs 
after stimulation with rAls3 in AD-HIES affected patients and healthy volunteers.  
2. Anti-rAls3 antibody titers at 6 months after vaccination in patients with AD-HIES and 
healthy volunteers. 
14 Ethics/Protection of Human Subjects 
 
Informed Consent Process 
Informed consent is a process where information is presented to enable persons to voluntarily 
decide whether or not to participate as a research participant. It is an ongoing conversation 
between the human research participant and the researchers that begins before consent is given 
and continues until the end of the participant’s involvement in the research. Discussions about 
the research will provide essential information about the study and include purpose, duration, 
experimental procedures, alternatives, risks, and benefits. Participants will be given the 
opportunity to ask questions and have them answered. 
The participants will sign the informed consent document before undergoing any research 
procedures. The participants may withdraw consent at any time throughout the course of the trial. 
A copy of the informed consent document will be given to the participants for their records. The 
researcher will document the signing of the consent form in the participant’s medical record. The 
rights and welfare of the participants will be protected by emphasizing to them that the quality of 
their medical care will not be adversely affected if they decline to participate in this study. 
 
Non-English-Speaking Participants 
If a non-English-speaking participant is unexpectedly eligible for enrollment, then the 
participant will be provided with the CC Short Written Consent Form for Non-English-Speaking 
Research Participants in the participant’s native language and a verbal explanation of the 
purpose, procedures, and risks of the study as described in Medical Administrative Series Policy 
M77-2, NIH HRPP SOP 12, and 45 CFR 46.117(b)(2). The IRB-approved English consent form 
will serve as basis for the verbal explanation of the study. The investigator will obtain an 
interpreter unless the investigator is fluent in the prospective participant’s language. Preferably, 
the interpreter will be someone who is independent of the participant (ie, not a family member). 
Interpreters provided by the CC will be used whenever possible. The interpreter will interpret all 
oral communications (English to target language and conversely) between the investigator and a 
limited-English-proficient participant, facilitate discussions, and clarify information as 
necessary. 
The IRB-approved English consent form will be signed by the investigator obtaining consent and 
a witness to the oral presentation. The CC Short Written Consent Form will be signed by the 
participant and a witness who observed the presentation of information. The interpreter may sign 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 42 of 47 
the consent document as the witness and, in this case, will note “Interpreter” under the signature 
line. A copy of both signed forms will be provided to the participant to take home. 
The investigator obtaining consent will document the consent process in the participant’s 
medical record (CRIMSON), including the name of the interpreter. Further, all instances of use 
of the CC Short Written Consent Form will be reported to the IRB at the time of annual review. 
If the CC Short Written Consent Form is used three times or more for the same language, this 
will be reported to the IRB immediately. 
 
Participant Confidentiality 
All records will be kept confidential to the extent provided by federal, state, and local law. The 
study monitors and other authorized representatives of the sponsor may inspect all documents 
and records required to be maintained by the investigator, including but not limited to, medical 
records. Records will be kept locked and all computer entry and networking programs will be 
done with coded numbers only. Clinical information will not be released without written 
permission of the subject, except as necessary for monitoring by IRB, the FDA, NIAID, OHRP, 
the pharmaceutical supporter, or the sponsor’s designee. 
15 Data Handling and Record Keeping 
 
Data Capture and Management  
Study data will be maintained in CRIMSON and collected directly from subjects during study 
visits and telephone calls, or will be abstracted from subjects’ medical records. Source 
documents include all recordings of observations or notations of clinical activities and all reports 
and records necessary to confirm the data abstracted for this study. Data entry into CRIMSON 
will be performed by authorized individuals. The investigator is responsible for assuring that the 
data collected are complete, accurate, and recorded in a timely manner. 
 
Record Retention 
The investigator is responsible for retaining all essential documents listed in the ICH GCP 
guidelines. The PI will maintain study records according to the timelines specified in 
21 CFR 312.62 or at a minimum of 5 to 7 years and in compliance with institutional, IRB, state, 
and federal medical records retention requirements, whichever is longest. All stored records will 
be kept confidential to the extent required by federal, state, and local law. 
Should the investigator wish to assign the study records to another party and/or move them to 
another location, the investigator will provide written notification of such intent to 
OCRPRO/NIAID with the name of the person who will accept responsibility for the transferred 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 43 of 47 
records and/or their new location. Destruction or relocation of research records will not proceed 
without written permission from OCRPRO/NIAID. 
 
 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 44 of 47 
16 Scientific References 
1. 
Liu Y, Filler SG. Candida albicans Als3, a multifunctional adhesin and invasin. 
Eukaryotic cell. 2011;10(2):168-173. 
2. 
Spellberg BJ, Ibrahim AS, Avanesian V, et al. Efficacy of the anti-Candida rAls3p-N or 
rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis. 
2006;194(2):256-260. 
3. 
Ibrahim AS, Luo G, Gebremariam T, et al. NDV-3 protects mice from vulvovaginal 
candidiasis through T- and B-cell immune response. Vaccine. 2013;31(47):5549-5556. 
4. 
Sheppard DC, Yeaman MR, Welch WH, et al. Functional and structural diversity in the 
Als protein family of Candida albicans. The Journal of biological chemistry. 
2004;279(29):30480-30489. 
5. 
Yeaman MR, Filler SG, Chaili S, et al. Mechanisms of NDV-3 vaccine efficacy in 
MRSA skin versus invasive infection. Proceedings of the National Academy of Sciences 
of the United States of America. 2014;111(51):E5555-5563. 
6. 
Yeaman MR, Filler SG, Schmidt CS, Ibrahim AS, Edwards JE, Jr., Hennessey JP, Jr. 
Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus 
aureus. Frontiers in immunology. 2014;5:463. 
7. 
NDV-3 Vaccine [investigator's brochure]. NovaDigm Therapeutics, Inc., Grand Forks, 
ND; February 2013. 
8. 
Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX, a 
polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase 
III clinical trials. Vaccine. 2004;22(7):880-887. 
9. 
O'Brien CN, Guidry AJ, Fattom A, Shepherd S, Douglass LW, Westhoff DC. Production 
of antibodies to Staphylococcus aureus serotypes 5, 8, and 336 using poly(DL-lactide-co-
glycolide) microspheres. Journal of dairy science. 2000;83(8):1758-1766. 
10. 
DeJonge M, Burchfield D, Bloom B, et al. Clinical trial of safety and efficacy of INH-
A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature 
infants. The Journal of pediatrics. 2007;151(3):260-265, 265 e261. 
11. 
Harro CD, Betts RF, Hartzel JS, et al. The immunogenicity and safety of different 
formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I 
studies. Vaccine. 2012;30(9):1729-1736. 
12. 
Fowler VG, Allen KB, Moreira ED, et al. Effect of an investigational vaccine for 
preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized 
trial. JAMA. 2013;309(13):1368-1378. 
13. 
Anderson AS, Miller AA, Donald RG, et al. Development of a multicomponent 
Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. 
Human vaccines & immunotherapeutics. 2012;8(11):1585-1594. 
14. 
Sowerwine KJ, Holland SM, Freeman AF. Hyper-IgE syndrome update. Annals of the 
New York Academy of Sciences. 2012;1250:25-32. 
 
 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 45 of 47 
Appendix A: Schedule of Procedures/Evaluations 
Evaluation 
Study day 
Early 
termination 
visit 
Screening 
(−28 to 
baseline) 
Baseline 
(−3 to -1 
and 0)a 
Post-
Vaccine 
(1 to 2) 
14 
(± 3) 
30b 
(± 3) 
42c 
(± 7) 
60b 
(± 3) 
90b 
(± 3) 
120b 
(± 3) 
150b 
(± 3) 
180 
(± 14) 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
Medical history 
Xd 
X 
 
 
 
 
 
 
 
 
 
 
Urine drug screening 
Xd 
 
 
 
 
 
 
 
 
 
 
 
Assessment of AEs 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Vaccination 
 
Xe 
 
 
 
 
 
 
 
 
 
 
Physical examf 
Xd 
X 
X 
X 
 
 
 
 
 
 
X 
X 
Review of concomitant 
medications 
Xd 
 
 
X 
X 
 
X 
X 
X 
X 
X 
X 
Blood for screeningg 
Xd 
 
 
 
 
 
 
 
 
 
 
 
History of Staph and 
Candida infections 
 
X 
 
X 
 
 
 
 
 
 
X 
X 
SCORAD assessment for 
eczemah 
 
X 
 
X 
 
 
 
 
 
 
X 
X 
Diary cardi 
 
 
 
X 
 
 
 
 
 
 
 
 
Research bloodj 
 
X 
Xk 
X 
 
X 
 
 
 
 
X 
X 
Saliva/vaginal secretionsl 
 
X 
 
X 
 
 
 
 
 
 
X 
X 
Stool, skin swab, 
oral/nasal/vaginal mucusl 
 
X 
 
X 
 
 
 
 
 
 
X 
X 
Research blood draw for 
CHI labsm 
 
Xn 
 
X 
 
 
 
 
 
 
X 
X 
Serum pregnancy test 
Xo 
Xp 
 
X 
 
 
 
 
 
 
 
 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 46 of 47 
AE = adverse event; PBMC = peripheral blood mononuclear cell; SCORAD = SCORing of atopic dermatitis. 
a 
Unless otherwise noted, baseline procedures will be conducted at only one of the visits, and will be scheduled depending on the investigators’ and participant’s convenience. 
b 
Evaluations on Days 30, 60, 90, 120, and 150 will be conducted over the phone. 
c 
Visit at Day 42 is optional and can be performed remotely (ie, blood is shipped from doctor or laboratory to NIH) at the convenience of the participant. 
d 
All healthy volunteers will undergo this screening evaluation. For participants with AD-HIES, this screening evaluation will only be conducted if it has not been done under the 
referring protocol (#00-I-0159) within 28 days before screening. 
e 
Vaccine administration will be conducted on Day 0 after all baseline evaluations are complete. 
f 
Complete physical exam with vital signs. 
g 
Blood for screening is for hepatitis B, hepatitis C, and HIV testing; acute, hepatic, and mineral panels; prothrombin/partial thromboplastin time; complete blood count with 
differential; lymphocyte flow cytometry; and serum immunoglobin quantitation. 
h 
For participants with AD-HIES only. 
i 
Diary card for recording of post-vaccination reactions will be provided to the participant on Day 0 after they receive the vaccination. The participant will fill out the diary card 
through Day 14 and then return it to the study team on Day 14. 
j 
Uses of research blood will include but are not limited ELISA for anti-rAls3 IgG and IgA1. 
k 
Day 1 only, for storage of PBMCs, serum, and RNA. 
l 
Vaginal and stool samples are optional. Skin, oral, and nasal may be collected. 
m PBMCs will be harvested from whole blood and transferred to the Center for Human Immunology, Autoimmunity and Inflammation (CHI) for storage and analysis. Research 
tests on PBMCs may include but are not limited to genetic testing, whole transcriptome sequencing, multiplex assays for inflammatory markers, and immunophenotyping. 
n 
Both baseline visits. 
o 
Test must be negative to confirm eligibility. 
p 
Day 0 only. Test must be negative before administration of the vaccine. 

NDV-3A Vaccine Study 
Protocol Version 3.0 
August 13, 2018 
Page 47 of 47 
Appendix B: Blood Draw Volumes 
Evaluation 
Study day 
Screening 
(−28 to 
baseline) 
Baseline 1 
(−3 to −1) 
Baseline 2 
(0) 
Post-Vaccine 
(1) 
14 
(± 3) 
42a 
(± 7) 
180 
(± 14) 
Blood draw volume (mL) 
Hepatitis B and C and HIV 
testing 
6b 
 
 
 
 
 
 
Chemistry panels (acute, 
hepatic, and mineral) 
4b 
 
 
 
 
 
 
PT/PTT 
4.5b 
 
 
 
 
 
 
CBC with differential 
3b 
 
 
 
 
 
 
Lymphocyte flow 
cytometry 
5b 
 
 
 
 
 
 
Serum immunoglobin 
quantitation 
4b 
 
 
 
 
 
 
Serum pregnancy testing 
4 
 
4 
 
4 
 
 
Serum for ELISA 
 
5c 
 
4 
5 
5 
5 
PBMCs for 
cryopreservation, DNA, 
and flow cytometry 
 
20 
20 
30 
40 
 
30 
PBMCs for whole 
transcriptome sequencing 
 
2.5 
2.5 
2.5 
2.5 
 
2.5 
PBMCs for multiplex 
assays 
 
4 
4 
 
4 
 
4 
Daily Volume 
30.5 
51.5 
40.5 
16.5 
55.5 
5 
41.5 
Cumulative Volume 
30.5 
82.0 
122.5 
139.0 
194.5 
199.5 
241.0 
CBC = complete blood count; CHI = Center for Human Immunology, Autoimmunity and Inflammation; ELISA = enzyme-linked immunosorbent assay; 
PBMC = peripheral blood mononuclear cell; PT/PTT = prothrombin time/partial thromboplastin time. 
a 
Visit at Day 42 is optional. 
b 
All healthy volunteers will undergo this screening evaluation. For participants with autosomal-dominant hyper-IgE syndrome, this screening evaluation will 
only be conducted if it has not been done under the referring protocol (#00-I-0159) within 28 days before screening. 
c 
Serum will be collected at only one of baseline visits, depending on the convenience of the participant and investigators.